STD Soulmates is one of the best HPV, Herpes Dating and other STD dating sites, online dating place for singles with STDs symptoms like Herpes, HPV Human Papiloma Virus, HIV and other sexually transmitted diseases who are looking for STD personals on line. Feel free to join our totally FREE dating service for lucky STD dating search.
The vaccine Gardasil [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] approved for treating the human papillomavirus in women, is now approved to treat the virus in males ages 9 to 26.
Today the U.S. Food and Drug Administration (FDA) has approved GARDASIL in males against genital warts caused by human papillomavirus (HPV) types 6 and 11.
A research study by Merck & Co. Inc.,the vaccine maker, showed that Gardasil prevented 90 per cent of cases of penile cancer and genital warts linked to four common HPV virus types (6, 11, 16, and 18) targeted by the vaccine.
It is estimated that HPV types 16 and 18 account for 70 percent of cervical and vaginal cancer and 6 and 11 cause approximately 90 percent of all genital warts cases.
You have to khow
GARDASIL may not fully protect everyone and does not exclude the necessity to continue to undergo recommended cervical cancer screening.
It does not treat cervical cancer or genital warts and will not protect against diseases caused by other HPV types.
The vaccine is one of the most costliest, its retail price is about $125 per dose ($375 for full series).
Merck is forecasting sales could top $2 billion this year.
Second HPV Vaccine approved in the U.S.
CERVARIX Human Papillomavirus Bivalent (Types 16 and 18) Vaccine is produced by GlaxoSmithKline (GSK), a British company.
It is called a bivalent vaccine because it targets two HPV types: 16 and 18.
This vaccine is also given in three doses over a 6-month period.
On 16 October 2009 GlaxoSmithKline (GSK) announced that the FDA approved Cervarix for the prevention of cervical cancer among females ages 10 to 25. Cervarix is already used in over 100 other countries.
The vaccine is expected to be available in the U.S. in late 2009. Cervarix is expected to cost about US $100 per dose.